Minor cannabinoid shows promise as measles virus fighter

Researchers have identified a promising minor cannabinoid called cannabichromevarin (CBCV) that may help fight measles virus infections at the molecular level. Using advanced computer simulations running for 1000 nanoseconds, scientists tested how various cannabinoids interact with the measles virus's fusion protein—the key structure the virus uses to invade cells. The results showed that CBCV outperformed conventional antiviral compounds, achieving superior binding efficiency and effectively stabilizing the virus's proteins in an inactive state, essentially freezing them before they can infect healthy cells.

Beyond raw antiviral potential, CBCV demonstrated exceptional drug development characteristics that real-world medications require. The compound showed excellent bioavailability, low toxicity, and the ability to cross the blood-brain barrier—a crucial property for treating neurological complications of measles, particularly Subacute Sclerosing Panencephalitis (SSPE), a devastating brain infection that can develop years after measles infection. The research suggests that minor cannabinoids previously considered less important than CBD or THC may have untapped therapeutic potential against viral diseases.

This computational study represents an important proof-of-concept that cannabinoids deserve further investigation as antiviral agents, expanding their potential medical applications far beyond pain, anxiety, and inflammation management. While these are computer-based predictions rather than clinical results, the findings open new research directions for leveraging cannabis chemistry in infectious disease treatment, particularly for challenging viral infections that currently lack effective therapeutic options.